Dr. Rini on Cytoreductive Nephrectomy in RCC

Video

In Partnership With:

Brian Rini, MD, associate professor, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, discusses the role of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma (RCC).

Brian Rini, MD, associate professor, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, discusses the role of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma (RCC).

For the last 20 years, subsequent cytoreductive nephrectomy and interferon has been the standard treatment for patients with metastatic RCC, Rini says. However, physicians are starting to rethink this decision because of the advent of targeted therapies.

Rini says several retrospective analyses have supported that cytoreductive nephrectomy should remain the standard treatment. However, patient selection bias prevents too much weight being placed on these retrospective studies, Rini says.

Two prospective studies are underway, but it will be some time before those read out.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD